To confirm the involvement of the TLR4/Myd88/NF-κB signaling pathway in the mitigating effects of CPGB on AD, we assessed pro-inflammatory responses and the activity of this signaling pathway in BV2 cells treated with STZ and 90 μg/mL (Low), 180 μg/mL (Mild), and 360 μg/mL (High) doses of CPGB. The gene discussed is MYD88; the disease is Alzheimer disease.